Source comparison
Hexarelin vs Ipamorelin: Mechanism Comparison
GHS-R1a Binding Affinity (nM) 0.7–1.2 nM (high affinity) 1.5–2.1 nM (moderate-high affinity) Hexarelin binds slightly tighter, producing stronger acute pulses CD36 Receptor Activity Yes. Cardioprotective signaling None. Ghrelin-selective only Hexarelin offers
This comparison does not assign a generated winner or score.
- GHS-R1a Binding Affinity (nM)
- 0.7–1.2 nM (high affinity)
- 1.5–2.1 nM (moderate-high affinity)
- Hexarelin binds slightly tighter, producing stronger acute pulses
- CD36 Receptor Activity
- Yes. Cardioprotective signaling
- None. Ghrelin-selective only
- Hexarelin offers cardiovascular benefits ipamorelin lacks
- Peak GH Amplitude (fold over baseline)
- 6–10× at 100mcg dose
- 2–4× at 100mcg dose
- Hexarelin produces 2–3× stronger GH release per dose
- Cortisol Elevation
- 20–35% increase at doses ≥100mcg
- Zero measurable increase at any dose
- Ipamorelin avoids HPA axis activation entirely
- Prolactin Elevation
- Moderate (15–25% increase)
- None
- Ipamorelin does not trigger lactotroph stimulation
- Desensitization Timeline
- 12–16 weeks of daily use
- No desensitization observed ≤24 weeks
- Hexarelin requires cycling; ipamorelin does not
- Optimal Dosing Frequency
- Once daily (100–200mcg)
- 2–3× daily (75–100mcg per dose)
- Ipamorelin benefits from split dosing to maintain GH elevation
- Half-Life (subcutaneous)
- 30–40 minutes
- 35–45 minutes
- Functionally identical clearance rates
- Primary Research Use Case
- Short-term peak GH protocols; cardiovascular studies
- Extended multi-month GH elevation; HPA-neutral studies
- Choose hexarelin for acute intensity; ipamorelin for sustainability